Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer
Standard
Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. / Lüftner, Diana; Schütz, Florian; Stickeler, Elmar; Fasching, Peter A; Janni, Wolfgang; Kolberg-Liedtke, Cornelia; Kolberg, Hans-Christian; Thomssen, Christoph; Müller, Volkmar; Fehm, Tanja N; Belleville, Erik; Bader, Simon; Untch, Michael; Welslau, Manfred; Thill, Marc; Tesch, Hans; Ditsch, Nina; Lux, Michael P; Wöckel, Achim; Aktas, Bahriye; Schneeweiss, Andreas; Würstlein, Rachel; Hartkopf, Andreas D.
In: GEBURTSH FRAUENHEILK, Vol. 82, No. 2, 02.2022, p. 215-225.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer
AU - Lüftner, Diana
AU - Schütz, Florian
AU - Stickeler, Elmar
AU - Fasching, Peter A
AU - Janni, Wolfgang
AU - Kolberg-Liedtke, Cornelia
AU - Kolberg, Hans-Christian
AU - Thomssen, Christoph
AU - Müller, Volkmar
AU - Fehm, Tanja N
AU - Belleville, Erik
AU - Bader, Simon
AU - Untch, Michael
AU - Welslau, Manfred
AU - Thill, Marc
AU - Tesch, Hans
AU - Ditsch, Nina
AU - Lux, Michael P
AU - Wöckel, Achim
AU - Aktas, Bahriye
AU - Schneeweiss, Andreas
AU - Würstlein, Rachel
AU - Hartkopf, Andreas D
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
PY - 2022/2
Y1 - 2022/2
N2 - Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.
AB - Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.
U2 - 10.1055/a-1724-9569
DO - 10.1055/a-1724-9569
M3 - SCORING: Review article
C2 - 35169389
VL - 82
SP - 215
EP - 225
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 2
ER -